Co-Authors
This is a "connection" page, showing publications co-authored by Waldemar Debinski and Ralph D'Agostino.
Connection Strength
0.653
-
Rossmeisl JH, Herpai D, Quigley M, Cecere TE, Robertson JL, D'Agostino RB, Hinckley J, Tatter SB, Dickinson PJ, Debinski W. Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas. Neuro Oncol. 2021 03 25; 23(3):422-434.
Score: 0.193
-
Sharma P, Sonawane P, Herpai D, D'Agostino R, Rossmeisl J, Tatter S, Debinski W. Multireceptor targeting of glioblastoma. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa107.
Score: 0.185
-
Ferluga S, Tomé CM, Herpai DM, D'Agostino R, Debinski W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget. 2016 Sep 13; 7(37):59860-59876.
Score: 0.141
-
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020 09 16; 10(1):15195.
Score: 0.047
-
Hassan S, Pullikuth A, Nelson KC, Flores A, Karpova Y, Baiz D, Zhu S, Sui G, Huang Y, Choi YA, D'Agostino R, Hemal A, von Holzen U, Debinski W, Kulik G. ß2-adrenoreceptor Signaling Increases Therapy Resistance in Prostate Cancer by Upregulating MCL1. Mol Cancer Res. 2020 12; 18(12):1839-1848.
Score: 0.047
-
Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB, Watabe K. Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Res. 2018 08 01; 78(15):4316-4330.
Score: 0.040